We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Catabasis Pharmaceuticals Inc | NASDAQ:CATB | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 8.54 | 8.45 | 8.63 | 0 | 00:00:00 |
From Dec 2019 to Dec 2024
Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a biopharmaceutical company, today announced that Jill C. Milne, Ph.D., Chief Executive Officer, will present a corporate overview and provide information on its lead program QLS-215, which is in preclinical development for the treatment of hereditary angioedema, at the following upcoming virtual investor conferences:
Webcasts of the events can be accessed from the investors section of www.catabasis.com. Archived replays will be available for 30 days following the event.
About Catabasis
At Catabasis Pharmaceuticals, our mission is to bring hope with life-changing therapies to patients and families. Our lead program, QLS-215, is a monoclonal antibody inhibitor of plasma kallikrein in preclinical development for the treatment of hereditary angioedema.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210514005065/en/
Catabasis Contacts: Investor relations: Andrea Matthews investors@catabasis.com
Media: Elizabeth Higgins media@catabasis.com
1 Year Catabasis Pharmaceuticals Chart |
1 Month Catabasis Pharmaceuticals Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
